- Home
- JSPR vs PLRX Comparison
JSPR vs PLRX Comparison
Compare JSPR & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- PLRX
- Stock Information
- Founded
- JSPR 2018
- PLRX 2015
- Country
- JSPR United States
- PLRX United States
- Employees
- JSPR N/A
- PLRX 171
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- JSPR Health Care
- PLRX Health Care
- Exchange
- JSPR Nasdaq
- PLRX Nasdaq
- Market Cap
- JSPR 85.8M
- PLRX 90.9M
- IPO Year
- JSPR N/A
- PLRX 2020
- Fundamental
- Price
- JSPR $4.73
- PLRX $1.46
- Analyst Decision
- JSPR Strong Buy
- PLRX Hold
- Analyst Count
- JSPR 10
- PLRX 10
- Target Price
- JSPR $62.50
- PLRX $9.79
- AVG Volume (30 Days)
- JSPR 181.2K
- PLRX 1.1M
- Earning Date
- JSPR 05-13-2025
- PLRX 05-05-2025
- Dividend Yield
- JSPR N/A
- PLRX N/A
- EPS Growth
- JSPR N/A
- PLRX N/A
- EPS
- JSPR N/A
- PLRX N/A
- Revenue
- JSPR N/A
- PLRX N/A
- Revenue This Year
- JSPR N/A
- PLRX N/A
- Revenue Next Year
- JSPR N/A
- PLRX N/A
- P/E Ratio
- JSPR N/A
- PLRX N/A
- Revenue Growth
- JSPR N/A
- PLRX N/A
- 52 Week Low
- JSPR $3.13
- PLRX $1.10
- 52 Week High
- JSPR $26.84
- PLRX $16.52
- Technical
- Relative Strength Index (RSI)
- JSPR 53.34
- PLRX 38.69
- Support Level
- JSPR $3.87
- PLRX $1.10
- Resistance Level
- JSPR $4.99
- PLRX $1.59
- Average True Range (ATR)
- JSPR 0.40
- PLRX 0.11
- MACD
- JSPR 0.18
- PLRX 0.12
- Stochastic Oscillator
- JSPR 86.02
- PLRX 73.47
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.